Overview

Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer

Status:
Completed
Trial end date:
2003-02-01
Target enrollment:
Participant gender:
Summary
To compare the safety of efficacy of abarelix versus goserelin plus bicalutamide in patients with advanced or metastatic prostate cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Speciality European Pharma Limited
Treatments:
Abarelix
Bicalutamide
Goserelin